Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022
Rhea-AI Summary
Corvus Pharmaceuticals (Nasdaq: CRVS) announced a conference call and webcast scheduled for August 8, 2022, at 4:30 PM ET to report second quarter 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on Corvus' investor relations page, with a replay available for 90 days. Corvus focuses on developing novel therapies, including mupadolimab (CPI-006) and CPI-818, for the treatment of various cancers.
Positive
- Scheduled conference call demonstrates transparency in business operations.
- Upcoming financial results may provide insights into growth metrics and future guidance.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CRVS declined 1.29%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
BURLINGAME, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on August 8, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2022 financial results.
The conference call can be accessed by 1-844-825-9789 (toll-free domestic) or 1-412-317-5180 (international) and using the conference ID 10169996. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals report its second quarter 2022 financial results?
How can I access the Corvus Pharmaceuticals conference call?
What is the lead product candidate of Corvus Pharmaceuticals?
What clinical trials is Corvus Pharmaceuticals currently conducting?
